Securities code: 000504 securities abbreviation: Nanhua Bio-Medicineco.Ltd(000504) Announcement No.: 2022-008 Nanhua Bio-Medicineco.Ltd(000504)
Announcement on purchasing directors, supervisors and senior managers liability insurance
The company and all members of the board of directors and the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Nanhua Bio-Medicineco.Ltd(000504) (hereinafter referred to as “the company”) held the third meeting of the 11th board of directors and the second meeting of the 11th board of supervisors on January 25, 2022, and deliberated the proposal on purchasing directors’ and supervisors’ senior liability insurance respectively. In order to further improve the company’s risk control system, reduce operational risks, promote the company’s directors, supervisors and senior managers to fully exercise their rights and perform their duties within their respective responsibilities, and protect the rights and interests of the company and investors. The company plans to purchase director supervisor senior liability insurance for all directors, supervisors and senior managers of the company in accordance with the relevant provisions of the standards for the governance of listed companies, as follows:
1. Applicant: Nanhua Bio-Medicineco.Ltd(000504)
2. Insured: directors, supervisors and senior managers of the company
3. Insurer: authorize the company’s management to select the best
4. Compensation limit: any compensation claim and all compensation claims accumulate 20 million yuan / year
5. Total premium: no more than 250000 yuan / year
6. Insurance period: 12 months (it can be renewed or re insured every year)
The board of directors of the company requests the general meeting of shareholders to authorize the management representative to handle matters related to the director supervisor’s high liability insurance business.
According to the relevant provisions of the articles of association, all directors and supervisors of the company avoid voting on the relevant proposals on this matter, and the relevant proposals are directly submitted to the general meeting of shareholders for deliberation.
It is hereby announced.
Nanhua Bio-Medicineco.Ltd(000504)
January 26, 2022
